Dual inhibition of hepatic ACLY and ACSS2: A synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement

Dual inhibition of hepatic ACLY and ACSS2: A synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement

Inhibiting de novo lipogenesis (DNL) in hepatocytes is a promising strategy for treating metabolic fatty liver diseases. ACLY, a key enzyme in the DNL pathway, has become a therapeutic target for non-alcoholic fatty liver disease (NAFLD). However, its inhibition shows mixed outcomes, depending on in...

Full description

Saved in:
Bibliographic Details
Main Authors: Mengdi Zhang, Jinliang Ji, Yuanyuan Lei, Fujian Qin, Yitong Tao, Ning Li, Jinlei Bian, Zhiyu Li, Maode Lai, Zhixia Qiu
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Pharmacological Research
Subjects:
Non-alcoholic fatty liver disease (NAFLD)
De novo lipogenesis (DNL)
ATP citrate lyase (ACLY)
Acyl-coenzyme A synthetase short-chain family member 2 (ACSS2)
Acetyl-CoA
Fatty acid oxidation
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661825001318
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items